Datascope Announces Safeguard(TM) Hemostasis Device
MONTVALE, N.J., Dec. 8 /PRNewswire-FirstCall/ -- Datascope Corp. announced the
worldwide launch of Safeguard*, an innovative, inflatable pressure-dressing
designed to maintain hemostasis after manual compression for arterial
catheterization procedures. Safeguard will compete in an estimated $54 million
worldwide market for devices that assist manual compression. The company
believes that most of this market opportunity is currently in the U.S. Manual
compression is still used to control bleeding in a majority of an estimated 4.8
million catheterization procedures in the U.S. market.
Safeguard is a single-use adhesive dressing with an inflatable see-through
plastic bulb. The user places Safeguard over the patient's puncture wound site
and inflates the bulb with air from a syringe. The inflated bulb is inelastic
and provides consistent pressure over the wound site to maintain hemostasis.
The see-through bulb allows easy monitoring of the wound site.
After completing an evaluation of Safeguard at the Lenox Hill Hospital of New
York, Dr. Jeffrey Moses, Chief, Interventional Cardiology said that, "Safeguard
is easy to use, effective and reliable." The device proved effective at
maintaining hemostasis following femorally accessed coronary catheterization
procedures, adhering to wound sites reliably for hours, and producing no
complications.
"Because Safeguard is so effective and easy to use, we expect to see many
applications besides cath procedures where hemostasis needs to be maintained. Safeguard is off to a good start in the market," said Tim Shannon, VP of Sales
for Datascope's Interventional Products Division that manufactures and markets
Safeguard.
Datascope Corp. is a diversified medical device company that manufactures and
markets proprietary products for clinical health care markets in interventional
cardiology and radiology, cardiovascular and vascular surgery, anesthesiology,
emergency medicine and critical care.
This press release contains forward-looking statements that involve risks and
uncertainties that could cause actual results to differ materially from those
projected in the forward-looking statements, including but not limited to the
company's ability to gain market acceptance for the Safeguard pressure assisted
dressing.
* Patent Pending DATASOURCE: Datascope Corp.
CONTACT: Murray Pitkowsky, Senior VP and CFO of Datascope Corp., +1-201-307-5504 Web site: http://www.datascope.com/
|